title: Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro.
abstract: Previous report indicated that Interleukin-2 (IL-2) is able to inhibit the growth of IL-2-receptor-positive cancer cell lines without any involvement of the immune system, through IL-2-induced alterations of the cell cycle kinetics. In this study we provide evidence that IL-2 exerts anti-proliferative effect on three human malignant mesothelioma (MMe) cells in vitro, while no effects were observed on normal human mesothelial cell (HMC) primary cultures. The growth inhibitory effect of IL-2 on neoplastic cells appeared to depend on the baseline proliferative status of these cells. Indeed, in highly proliferating MMe cells, we observed a reduction of malignant cells in the S-phase of the cell cycle, with an accumulation in G0/G1, followed by apotosis for longer incubations or exposure to higher doses. On the contrary, in MMe cells proliferating at lower rate, IL-2 induces only a late cytotoxic effect, leading to apoptosis, without significantly affecting the cell cycle. IL-2Rbeta mRNA was detectable by RT-PCR in all MMe cells, IL-2Ralpha mRNA in one only out the three assayed and IL-2Rgamma mRNA in none. In addition, mRNA specific for the IL-2Rbeta-associated Jak-1 tyrosine kinase was expressed in all MMe cell lines, further suggesting that IL-2Rbeta may play a role in the observed effects. Very low, albeit detectable, levels of IL-2Rbeta chain appeared to be expressed at the cell surface of MMe cells by indirect immunofluorescence and FACS analyses. Finally, Ca(++) fluxes were rapidly induced when MMe cells were exposed to exogenous IL-2.
authors.affiliation: Laboratory of Cytometry and Cellular Therapies, A. Ferrata Institute of Internal Medicine and Medical Oncology, IRCCS San Matteo University Hospital, Pavia, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Porta
authors.forename: M
authors.initials: M
authors.lastname: Danova
authors.forename: A M
authors.initials: AM
authors.lastname: Orengo
authors.forename: S
authors.initials: S
authors.lastname: Ferrini
authors.forename: M
authors.initials: M
authors.lastname: Moroni
authors.forename: A
authors.initials: A
authors.lastname: Gaggero
authors.forename: R
authors.initials: R
authors.lastname: Libener
authors.forename: P G
authors.initials: PG
authors.lastname: Betta
authors.forename: S
authors.initials: S
authors.lastname: Ferrari
authors.forename: A
authors.initials: A
authors.lastname: Procopio
authors.forename: L
authors.initials: L
authors.lastname: Strizzi
authors.forename: L
authors.initials: L
authors.lastname: Mutti
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D008654:Mesothelioma / Q000473:pathology*; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2